Crinetics’ Paltusotine Future Appears Bright With First Phase III Acromegaly Readout

Crinetics Pharmaceuticals, Inc.’s paltusotine succeeded in the first of two Phase III clinical trials in acromegaly, showing that patients switching from standard-of-care monthly injectable somatostatin analogs (SSAs) maintained disease control with a once-daily oral therapy. The readout boosted confidence in upcoming Phase II and III readouts for the drug and its potential to take center stage as a commercial product that could become a market leader and a new standard of care.

San Diego-based Crinetics reported results from the Phase III PATHFNDR-1 trial on 10 September and after hosting a call on 11 September its stock closed up 63.3% at $26.08 per...